Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer - Wikidata - wikimedia - TriplyDB

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

http://www.wikidata.org/entity/Q34613941

about

Growth factor and signaling pathways and their relevance to prostate cancer therapeutics Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer SRC: marker or actor in prostate cancer aggressiveness Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Regulation of SRC family kinases in human cancers Novel non-AR therapeutic targets in castrate resistant prostate cancer Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.Recent advances in bone-targeted therapies of metastatic prostate cancer Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.Update on options for treatment of metastatic castration-resistant prostate cancer Emerging treatment options for patients with castration-resistant prostate cancer.Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration.Evolving role of bone biomarkers in castration-resistant prostate cancer.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.Novel therapies for metastatic castrate-resistant prostate cancer.A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.Targeted therapy in prostate cancer.Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases.New hormonal therapies for castration-resistant prostate cancer.miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.Emerging targeted therapies for castration-resistant prostate cancer.Future perspectives of prostate cancer therapy.Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.Activation of abl family kinases in solid tumors.SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.New and emerging therapies for bone metastases in genitourinary cancers.Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer

P2860

Q26827975-261B5E9F-86B5-4281-B624-1D1CAB0DA382 Q26866135-ABA1F8BF-5A32-4A4A-A859-3CE786B348A2 Q27010542-ACF87D81-B409-4742-BEF9-900360E069D6 Q27012541-6C4C8F21-A7DC-43B9-A093-A3775612D28F Q27021268-DAB4379E-1E12-4738-9562-97C378AB651A Q28082793-55A68A5D-CAE1-40EC-903D-B97C1E68E53F Q28243770-29C2A9D7-1605-4E2C-A4D4-1F84F9A62C35 Q28383663-08E84899-70A8-4D3F-B0F3-4350BA8B08C7 Q28484572-F5D8F44B-6E52-4903-B96C-C543DFE9CAAD Q30416923-09F9F13C-9BCD-425A-A18C-B0D12621A808 Q30433918-EC3FAA25-76F2-44EC-9D4B-7E82AEDE92C5 Q33404541-49742D42-10FB-4E2A-8A3F-B25C06D46792 Q33415009-48F8FBAB-35FE-43A3-A6C2-269413087231 Q33703763-38E7647B-EC85-46E6-B568-4D93483ABB61 Q33946929-F1EAAB27-67FF-4D63-8C5C-20AA90C4ECD5 Q33956051-BB8C8EC4-1AF0-420C-ABCC-6125C5A1759F Q33958519-4CC9638B-1465-4B32-B68E-ABA2A02B5D01 Q33958982-9911A0E2-64C2-426D-9C7B-0430E49E1365 Q34023877-68690433-6D47-4765-A887-CF6E6021CF4D Q34121339-71EAF758-CB3A-41A5-965F-F3930E81F5E3 Q34194110-E06FEC69-78BD-4644-8067-287BBD17D486 Q34249263-4BC14131-8849-42B5-BE3F-83457DDC96D0 Q34322294-C6A1946D-C2B5-4131-A43B-1C05DC918D63 Q34448130-CC5E2DB4-45E2-4FEA-8AF9-C17F0FE04A20 Q34518357-EA22A804-DCD6-4C79-B4DB-294F2E5D8E8D Q34634763-55D0F13A-D09F-4904-A20D-1CF76F698FBF Q34708878-7EA9F775-F026-4C02-BFB8-702F6E881CFE Q35040740-34AAA062-2859-4868-B435-6AFA5CE1861A Q35196715-442B4A5C-63B7-4FB4-954F-518D2759AC74 Q35207623-02CFAD22-D0FE-42F4-8445-B289E524FE7C Q35541792-24BE0928-8A20-49A9-AD23-905C1B94E4D8 Q35555303-02D5A2F5-2C28-48FB-A418-A976758908E6 Q35999255-A5404683-5CB0-4AC8-AE85-9021C8E9AA99 Q36076453-FD07BF9C-50D0-43A3-81B3-8A5A91E64665 Q36087899-732B5EE4-FAD2-4B0E-8741-BF41E7EAA536 Q36243296-0C15576D-B1B6-4058-BD4F-A25EAE8C262B Q36443421-3C1334CD-B14F-4E26-9997-75600F21A34C Q36688923-1F2D1472-4E07-4173-8738-34667D20A8AD Q36866291-69A23709-B444-4A58-9D2D-180888EE6A7F Q36900805-2CFEE4F9-C63C-4FB4-9D8C-70233C7BB7BA

P2860

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

http://www.wikidata.org/entity/Q34613941

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase II study of dasatinib in ...... tion-resistant prostate cancer

@ast

Phase II study of dasatinib in ...... tion-resistant prostate cancer

@en

Phase II study of dasatinib in ...... tion-resistant prostate cancer

@nl

type

label

Phase II study of dasatinib in ...... tion-resistant prostate cancer

@ast

Phase II study of dasatinib in ...... tion-resistant prostate cancer

@en

Phase II study of dasatinib in ...... tion-resistant prostate cancer

@nl

prefLabel

Phase II study of dasatinib in ...... tion-resistant prostate cancer

@ast

Phase II study of dasatinib in ...... tion-resistant prostate cancer

@en

Phase II study of dasatinib in ...... tion-resistant prostate cancer

@nl

P1433

Q34613941-4DA01F7B-ED9C-472E-8931-1EC10BDA9B67

P1476

Q34613941-02564D66-90BF-49A1-8616-A5AE3A7AF535

P2093

Q34613941-0798E5F7-8306-4C28-A1C2-8268FDC7A011

Q34613941-2548392F-56D6-4005-BA6F-B9D498F19CF6

Q34613941-274B196F-2BE1-43E7-B0B7-DE4587EAAF13

Q34613941-278D6888-F6A9-4082-9B74-22D1A7858F6D

Q34613941-32679CF2-331E-4E6E-947C-7EE69518382D

Q34613941-47FD18DF-FB97-4E37-A253-290F371ECD57

Q34613941-5AED4019-471A-49B0-A5A0-90A759AC3DCC

Q34613941-64CDD494-C0B6-4455-A342-5565733F6CE8

Q34613941-A15271A9-2C14-4C8B-ACD4-647BE5A7274B

Q34613941-A6F179F1-E166-4CD6-A78F-C12B11E0DF59

P2860

Q34613941-09D492F2-40BF-40BA-9C66-E79AE9FCBE05

Q34613941-122A8E11-16D9-4582-B9D8-FD8B44141699

Q34613941-15555834-D70D-4073-B513-D77B796930EB

Q34613941-169D314B-3D67-4EE7-97C7-55BCD02065C8

Q34613941-23D425A0-3C1F-4E87-8D2E-B7B0FA026015

Q34613941-2A00C98D-2C02-4963-AD27-E7363220A053

Q34613941-2F01CC9D-D8D6-4019-B960-28DD91672DDC

Q34613941-3306C86D-014D-4507-9484-BB5C2901BFE9

Q34613941-332F54F2-FF81-4DD7-A3C0-8B85FF3E64B6

Q34613941-3F94D3CA-584F-47F5-8CBE-99D5DDB882AB

P304

Q34613941-FCBB9AF1-9B3D-49C7-B138-2A6F5C2ED292

P31

Q34613941-881882C8-D035-4952-9469-47D712E0B5AC

P356

Q34613941-7F0D0DBB-9AC3-4396-8025-D46E36353541

P407

Q34613941-45A0E8A1-E8D8-492E-99EE-2CFF0831EB38

P433

Q34613941-56AF64E0-68A2-4A01-8268-BD6565ED1A28

P478

Q34613941-65E6E131-A65E-41A1-BA67-9DD5CF896AD0

P50

Q34613941-E37E263D-92BE-458D-8B32-DFD490C3C198

P577

Q34613941-7A1FC8F1-70FD-49A0-A935-EE86A642F38B

P5875

Q34613941-7B10AC7B-8893-4207-AB0D-12E9B980D3E5

P698

Q34613941-917FBDCB-90C6-4CF3-B049-134CB834A33B

P932

Q34613941-E47AA93A-CD11-42D6-ABA9-B48FFA63D69B

P356

1078-0432.CCR-09-1691

P1433

Clinical Cancer Research

P1476

Phase II study of dasatinib in ...... tion-resistant prostate cancer

@en

P2093

Christophe Massard

http://www.w3.org/2001/XMLSchema#string

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

Edwin Posadas

http://www.w3.org/2001/XMLSchema#string

Evan Y Yu

http://www.w3.org/2001/XMLSchema#string

Fabio Calabrò

http://www.w3.org/2001/XMLSchema#string

Gary Hudes

http://www.w3.org/2001/XMLSchema#string

Géralyn C Trudel

http://www.w3.org/2001/XMLSchema#string

Michael J Morris

http://www.w3.org/2001/XMLSchema#string

Mitchell Gross

http://www.w3.org/2001/XMLSchema#string

Prashni Paliwal

http://www.w3.org/2001/XMLSchema#string

P2860

Src family kinases in tumor progression and metastasis

Cancer statistics, 2008

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

FYN is overexpressed in human prostate cancer

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Biochemical markers and skeletal metastases.

P304

7421-7428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-1691

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38095927

http://www.w3.org/2001/XMLSchema#string

P698

19920114

http://www.w3.org/2001/XMLSchema#string

P932

3394097

http://www.w3.org/2001/XMLSchema#string